J Ophthalmol:健康人的施莱姆管和眼压在运动后可以正常恢复到运动前水平

2018-10-08 MedSci MedSci原创

华中科技大学同济医学院附属同济医院眼科的Li M和Yan X等近日在J Ophthalmol杂志上发表了一篇文章,他们观察了健康人运动后施莱姆管(SC)和眼压(IOP)的恢复过程。

华中科技大学同济医学院附属同济医院眼科的Li M和Yan X等近日在J Ophthalmol杂志上发表了一篇文章,他们观察了健康人运动后施莱姆管(SC)和眼压(IOP)的恢复过程。

他们招募了20个健康个体。在运动前和运动后0、15、30和60分钟时评估SC和IOP。使用扫描光学相干断层扫描技术(SS-OCT)评估上、下、鼻象限和时间象限施莱姆管(SC)的情况。

结果他们发现,运动前后平均SC面积为3726.81±1167.06 vs. 4660.57±1284.82μm2,周长为324.11±58.95 vs. 367.19±73.34μm,运动后增加,运动期间IOP(14.02±2.33 vs. 11.65±1.90 mmHg)显着下降(所有p < 0.001)。运动后,SC和IOP均恢复至运动前的水平,运动后SC大小的的恢复时间为15分钟,短于眼压的恢复时间(60分钟)。在调整年龄、性别、眼轴长度、中央角膜厚度和球面等效后,运动后的SC尺寸的变化与运动后的IPO变化没有显着的相关性(均p> 0.05)。在运动前后SC比例也没有显着差异(均p> 0.05)。

因此,他们认为,运动诱导的SC扩张和眼压降低,在运动后可以恢复到运动前的水平,并且SC比IPO先恢复到运动前的水平。此外,SC可能受交感神经的调节,可能是运动期间IOP变化的重要诱发因素。

原文出处:

Li, M., et al., Postexercise Recovery of Schlemm's Canal and Intraocular Pressure in Healthy Individuals: An Observational Study Using Swept-Source Optical Coherence Tomography. J Ophthalmol, 2018. 2018: p. 8513760.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911122, encodeId=45c919111222c, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Jan 22 15:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293999, encodeId=d4c3129399975, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541398, encodeId=4a5f154139824, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348525, encodeId=b543348525fd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Oct 08 21:05:53 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911122, encodeId=45c919111222c, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Jan 22 15:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293999, encodeId=d4c3129399975, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541398, encodeId=4a5f154139824, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348525, encodeId=b543348525fd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Oct 08 21:05:53 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-10 swallow
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911122, encodeId=45c919111222c, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Jan 22 15:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293999, encodeId=d4c3129399975, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541398, encodeId=4a5f154139824, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348525, encodeId=b543348525fd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Oct 08 21:05:53 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911122, encodeId=45c919111222c, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Jan 22 15:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293999, encodeId=d4c3129399975, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541398, encodeId=4a5f154139824, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Oct 10 11:45:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348525, encodeId=b543348525fd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Oct 08 21:05:53 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 医者仁心5538

    学习了

    0

相关资讯

Diabetes:依帕列净与健康人和2型糖尿病患者的肾脏葡萄糖转运动力学分析!

总而言之,钠葡萄糖共转运体2的抑制剂依帕列净可以降低TmG和葡萄糖从尿液中溢出的阈值,无论是2型糖尿病患者,还是非糖尿病患者。

Hypertension:健康人血压受神经型一氧化氮合酶调节!

这些结果表明,nNOS来源的NO在健康人基础的全身血管阻力和血压的生理调节中发挥着重要作用。

Lancet:重大进展!新的HIV候选疫苗可安全地在健康人和猴子中诱导出强效的免疫反应

一项新的研究表明一种实验性HIV-1候选疫苗具有良好的耐受性,并且可在健康的成年人和恒河猴中产生可比较的强效免疫反应。此外,这种候选疫苗能够让猴子免受猿猴-人类免疫缺损病毒(simian-human immunodeficiency virus, SHIV)---一种类似于HIV的感染猴子的病毒---感染。相关研究结果于2018年7月6日在线发表在The Lancet期刊上,论文标题为“Evalu

Clin Sci:即使

高糖饮食与心血管疾病风险之间存在过去未曾发现的关联,即使对于那些健康的人来说也是如此。摄入大量糖的健康人患心血管疾病的风险会增高。